# Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).

> **NCT06737354** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **InnoVec Biotherapeutics Inc.** · enrollment: 18 (estimated)

## Conditions studied

- nAMD

## Interventions

- **GENETIC:** IVB103 Injection（Low dose）
- **GENETIC:** IVB103 Injection（Intermediate dose）
- **GENETIC:** IVB103 Injection（High dose）

## Key facts

- **NCT ID:** NCT06737354
- **Lead sponsor:** InnoVec Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-04-22
- **Primary completion:** 2027-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06737354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06737354, "Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06737354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*